Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.

摘要: Neuroendocrine tumors (NETs) are rare that have been increasing in incidence over the last 30 years with no significant changes survival. As survival of patients these depends greatly on stage and histology, early diagnosis, classification staging whom NETs suspected great importance. Surgery, either curative or palliative intent, is mainstay treatment for localized NETs. Therapeutic options this disease almost invariably include somatostatin analogs to alleviate symptoms excessive hormone secretion. Other approaches advanced may hepatic artery embolization ablation, peptide receptor radionuclide therapy systemic chemotherapy. Recent advances regarding signaling pathways involved tumor development allowed novel targeted therapies. However, due lack prognostic molecular markers identify high-risk absence a common pathogenesis all patients, selection often empirical. There therefore need establish consensus provide evidence-based clinical recommendations algorithms optimize individualize follow-up patients.